Understanding antidepressant clinical trial results: Dextromethorphan-bupropion (Auvelity®)

In August 2022, the United States Food and Drug Administration (FDA) approved the combination of dextromethorphan and bupropion (brand name Auvelity®) for the treatment of major depressive disorder (MDD). Note that the FDA indication is NOT for “treatment-resistant” major depressive disorder or major depressive disorder that has not responded adequately to a previous trial of…